INTERIM RESULTS for the six months ended 30 June 2025

ImmuPharma PLC (LSE:IMM), (“ImmuPharma”, the Group or the “Company”), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2025 (the “Period”).

Key Highlights (including post Period review)

Financials

For the period ended 30 June 2025, the Group reported a loss of £1.8 million, compared to a loss of £0.4 million for the same period in 2024. This increase is attributable to higher operational costs, in research and development, which rose to £0.7 million from £0.5 million in the previous year. Administrative expenses amounted to £0.4 million, a small increase from £0.3 million in 2024 and in addition to a loss on revaluation of the derivative financial asset of £0.7 million compared to a gain of £0.2 million in the same period for 2024. Share-based payments for the period were £0.05 million, compared with £0.03 million in the prior period.

As at 30 June 2025, the Group held a cash balance of £0.4 million, representing a decrease from £1.1 million at 30 June 2024. The derivative financial asset was valued at £0.6 million, up from £0.5 million a year earlier. The basic and diluted loss per share for the period was 0.38 pence, compared to 0.09 pence in the previous year.

Portfolio

P140 technology platform

• In January 2025, innovative groundbreaking advancements announced in our preclinical research program focused on our P140 technology platform and the pathogenesis (the process by which diseases develop) of autoimmune diseases. These findings pave the way for earlier and more accurate diagnostics; identifying patients most likely to respond to P140 therapy; and improved monitoring of the patient’s response to treatment with P140
• In March 2025 a significant milestone announced in evidencing for the first time key hypotheses in the unique mechanism of action (“MOA”) of our P140 autoimmune technology platform. Importantly, these new discoveries highlight that: P140 has a unique MOA, is non‐immunosuppressive, and is effective and safe
• The favourable impact of P140 on immune system homeostasis (creating a stable internal environment) also supports P140 as a new potential standard of care for patients suffering from a multitude of autoimmune diseases, that are caused by the same underlying immune system malfunction. This also agrees with many preclinical models of autoimmune diseases where P140 has clearly demonstrated efficacy
• These findings will allow ImmuPharma to further expand its intellectual property portfolio, with additional new patents, strengthening the commercial viability of the P140 technology platform

Partnering opportunities

• Based on recent progress and insights into the P140’s MOA and autoimmune disease, active discussions continue with potential global commercial partners

Preclinical Portfolio

• The core anti-infective program with antifungal (BioAMB) and antibacterial (BioCIN) candidates are progressing through pre-clinical studies

Incanthera

• As confirmed on 1 April 2025, the warrants of 7,272,740 held in Incanthera, have been further extended to 30 September 2025, alongside a profit share agreement, if the warrant shares are exercised

Commenting on the statement and outlook Tim McCarthy, CEO and Chairman, said:

“We have made significant scientific progress over 2024 and into 2025, most importantly, announcing innovative groundbreaking advancements in our P140 technology platform and the pathogenesis of autoimmune diseases. This paves the way for earlier and more accurate diagnostics; identifying patients most likely to respond to P140 therapy; and improved monitoring of the patient’s response to treatment with P140.

In addition, we also announced a significant milestone in evidencing for the first time, key hypotheses in the unique mechanism of action (“MOA”) of our P140 autoimmune technology platform. These new discoveries highlight that: P140 has a unique MOA, is non‐immunosuppressive, and is effective and safe.

As a Board, we remain focused on bringing our two key late-stage clinical assets, P140 for SLE and CIDP, closer to the market, and securing additional global partnering deals for P140 together with our earlier stage assets.

In closing, we would like to thank our shareholders for their support as well as our staff, corporate and scientific advisers and our partners including CNRS and Avion.”

To view this announcement including Interim Results document click here

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.